Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2000-12-11 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Ad hoc-Service: MorphoSys AG
Regulatory Filings Classification · 99% confidence The document is a short press release dated December 11, 2000, announcing a specific business event: achieving a milestone in a collaboration agreement with Roche regarding Alzheimer's drug development. It details the nature of the agreement, the payment received, and the responsibilities of each party. This type of announcement, focusing on a specific corporate transaction or development outside of routine financial reporting (like earnings or annual reports), best fits the category for general regulatory announcements or corporate news that doesn't fit a more specific financial or governance code. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a capital event (CAP, SHA), the most appropriate classification is the general regulatory/news filing category, RNS, as it is an 'Ad hoc-Service' announcement.
2000-12-11 German
Ad hoc-Service: MorphoSys AG
Environmental & Social Information Classification · 99% confidence The document is a short, dated announcement (Ad-hoc Service, December 5, 2000) detailing a specific technological development by MorphoSys (CysDisplay) and its application to antibody generation. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). It announces a new technical capability and patent filing, which falls under general corporate or investor news that doesn't fit the highly specific categories like M&A, Dividends, or Director's Dealing. Given its nature as a specific, non-standard corporate update, the most appropriate fallback category is Regulatory Filings (RNS), as it is an 'Ad hoc' announcement.
2000-12-05 German
Ad hoc-Service: MorphoSys AG
Earnings Release Classification · 99% confidence The document is a short press release dated November 29, 2000, announcing a specific operational achievement (a milestone) in a collaboration between MorphoSys AG and ProChon Biotech Ltd. regarding antibody development. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management change (MANG). It details a specific business development, which often falls under general regulatory announcements or news releases. Given the options, this type of specific, non-financial, operational news release that doesn't fit other specific categories (like M&A, Capital Change) is best classified as a general Regulatory Filing (RNS), as it is an 'Ad hoc-Service' announcement. Q4 2000
2000-11-29 German
Ad hoc-Service: MorphoSys AG
Earnings Release Classification · 100% confidence The document is titled 'MorphoSys veroeffentlicht 9-Monatsbericht' (MorphoSys publishes 9-Month Report) and provides detailed financial figures for the first nine months of the year 2000, including revenues, operating expenses, and net loss per share, comparing them to the previous year's corresponding period. This content structure—a comprehensive financial summary for a period shorter than a full year (nine months)—is characteristic of an Interim/Quarterly Report. Although it is an announcement, the core content provided is the summary of the report itself, not just a notice that a report is available. Therefore, it aligns best with the Interim / Quarterly Report (IR) definition, rather than the Report Publication Announcement (RPA). 9M 2000
2000-11-14 German
Ad hoc-Service: MorphoSys AG
Regulatory Filings Classification · 100% confidence The document is a short press release dated October 2, 2000, announcing a collaboration agreement between MorphoSys AG and ImmunoGen regarding the development of therapeutic antibodies for cancer treatment. It details the terms (technology access payment, milestones, royalties) but does not contain comprehensive financial statements, management discussion, or formal regulatory filing headers (like 10-K or IR). This type of announcement, detailing a significant business development (a partnership/deal), is best classified as a general regulatory announcement or news release that doesn't fit the more specific financial report categories. Since it is a specific business development announcement, and not a general regulatory filing fallback (RNS), the closest fit among the options for a significant business transaction announcement that isn't M&A (TAR) or Capital Change (CAP) is often categorized under general regulatory news, but given the options, it most closely resembles a significant business event announcement. However, none of the codes perfectly capture a 'Business Development Announcement'. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category for a short, ad-hoc press release detailing a strategic partnership that doesn't fit the other specific financial or reporting codes.
2000-10-01 German
Ad hoc-Service: MorphoSys AG
Regulatory Filings Classification · 96% confidence The document is a short announcement dated September 25, 2000, labeled as 'Ad-hoc-Service'. It details the successful completion of a milestone in a collaboration between MorphoSys AG and GPC Biotech regarding antibody development for treating transplant rejection. It mentions a milestone payment received by MorphoSys and the next steps (pre-clinical studies). This type of immediate, material business update, especially one concerning research progress and associated payments, fits best under a general regulatory announcement category. Since it is not a formal financial report (10-K, IR, ER), a specific legal update (LTR), or a management change (MANG), the most appropriate classification is the general regulatory filing fallback, RNS, as it is an 'Ad hoc' announcement.
2000-09-25 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.